Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | CTSA | P10619 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MGAM | O43451 | 2/20 | 0.46 |
| ▸ | SI | P14410 | 2/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30668080 | 1.00 | PDPK1 (0.60) | PDPK1CYP2A6CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL15805858 | 0.86 | PDPK1 (0.72) | PDPK1CYP2A6LOXL2RAB9APTGDR2 | |
| SCHEMBL16159287 | 0.82 | PDPK1 (0.67) | PDPK1CYP2A6LOXL2RAB9APTGDR2 | |
| SCHEMBL31247668 | 0.82 | CYP19A1 (0.44) | PDPK1CYP19A1CTSANPC1RAB9A | |
| SCHEMBL4425765 | 0.79 | PDPK1 (0.74) | PDPK1CYP2A6LOXL2CTSARAB9A | |
| SCHEMBL4762632 | 0.79 | CYP1A1 (0.49) | PDPK1CYP2A6CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL14060556 | 0.78 | CYP1A1 (0.61) | PDPK1CYP1A1CYP1A2CYP1B1FBP1 | |
| SCHEMBL173979 | 0.78 | PDPK1 (0.60) | PDPK1CYP2A6CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL11153399 | 0.78 | PDPK1 (0.60) | PDPK1CYP2A6LOXL2RAB9APTGDR2 | |
| SCHEMBL20550702 | 0.78 | PDPK1 (0.60) | PDPK1CYP2A6CYP19A1LOXL2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104829550-B | The method efficiently preparing o-hydroxy-phenyl heterocyclic derivative based on transition metal-catalyzed C-H/C-H oxidative coupling reaction | 四川大学 | 2016-10-05 | — | — | CN | claimed |
| EP-0271260-A2 | Supersensitization of silver halide emulsions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1988-06-15 | — | — | EP | claimed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-114939117-A | Method of treating vascular leak syndrome | 视点制药公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220211675-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | EyePoint, Inc. | 2022-07-07 | — | — | US | disclosed |
| CN-114269341-A | Tie-2 activator targeting Schlemm's canal | 视点制药公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11253502-B2 | Tie-2 activators targeting the Schlemm's canal | EyePoint Pharmaceuticals, Inc. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| WO-2020223209-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | Aerpio Pharmaceuticals, Inc. (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20200338048-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | EyePoint, Inc. | 2020-10-29 | — | — | US | disclosed |
| US-20060202197-A1 | Platinum complex and light-emitting device | TAKASAGO INTERNATIONAL CORPORATION | 2006-09-14 | — | — | US | disclosed |
| EP-1683804-A2 | PLATINUM COMPLEX AND LUMINESCENT ELEMENT | Takasago International Corporation (JP) | 2006-07-26 | — | — | EP | disclosed |
| WO-1999032466-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVARTIS AG (CH) | 1999-07-01 | — | — | WO | disclosed |
| US-5691125-A | CYAN DYE-FORMING COUPLER, STORAGE STABLE | FUJI PHOTO FILM CO., LTD. (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0563985-A1 | Silver halide color photographic material | Fuji Photo Film Co., Ltd. (JP) | 1993-10-06 | — | — | EP | disclosed |
| EP-0383265-A2 | Method for forming color image | FUJI PHOTO FILM CO., LTD. (JP) | 1990-08-22 | — | — | EP | disclosed |
| EP-0138543-A2 | Silver halide photographic light sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1985-04-24 | — | — | EP | disclosed |
| EP-0123983-A2 | Silver halide photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1984-11-07 | — | — | EP | disclosed |
| EP-0048834-A1 | Method for measurement of trace enzymes | FUJI PHOTO FILM CO., LTD. (JP) | 1982-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211675-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | TIE1, TEK, TGFB2 | PDPK1 1101/4885CYP2A6 4612/4885CYP1A1 4825/4885 |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | PDPK1 485/4885CYP2A6 4675/4885CYP1A1 4872/4885 |
| US-11253502-B2 | Tie-2 activators targeting the Schlemm's canal | TIE1, TEK, TGFB2 | PDPK1 1101/4885CYP2A6 4612/4885CYP1A1 4825/4885 |
| US-20200338048-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | TIE1, TEK, TGFB2 | PDPK1 1101/4885CYP2A6 4612/4885CYP1A1 4825/4885 |
| US-20060202197-A1 | Platinum complex and light-emitting device | RAD1, RAD51, UACA | PDPK1 2341/4885CYP2A6 2525/4885CYP1A1 845/4885 |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PDPK1 232/4885CYP2A6 4359/4885CYP1A1 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.